What could help biotech close out 2019 stronger? Analysts pick 3 events to watch

Biotech generally underperformed the market so far this year. Updates from Amgen, Roche and Novartis could deliver a needed boost, analysts at Credit Suisse say.

By Andrew Dunn • Sept. 4, 2019

Vertex to buy preclinical biotech for $950M, searching a Type 1 diabetes cure

Acquiring Semma Therapeutics fulfills CEO Jeffrey Leiden's promise that Vertex would explore "potentially larger" deals than it's done in the past.

By Andrew Dunn • Sept. 3, 2019

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

UniQure stays a step ahead in hemophilia B

Seeing high interest from patients and study investigators, uniQure is enrolling six more participants than planned in its Phase 3 gene therapy study.

By Ned Pagliarulo • Sept. 3, 2019

Medicines Co.'s cholesterol drug looks good to take on PCSK9 rivals

Data show inclisiran more or less matched Repatha and Praluent on cholesterol lowering, but the drug will need a smart launch, and possibly a partner, to compete.

By Jonathan Gardner • Updated Sept. 3, 2019

Alexion shares slide on Amgen patent challenge to top-seller

A surprise decision by the U.S. patent office to review three patents held by Alexion on its drug Soliris renewed fears of earlier-than-expected competition.

By Ned Pagliarulo • Aug. 30, 2019

Amgen puts its KRAS hopes on 'Navy Seals' team of drug hunters

Found in many solid tumors, mutant KRAS is cancer research's white whale. Amgen's drug looks the most promising to emerge from decades of failed efforts, but others are close behind. 

By Ned Pagliarulo • Aug. 30, 2019

Amyloid's last hope? Prevention studies next big test for Alzheimer's research

The DIAN-TU trial, studying patients genetically predisposed to Alzheimer's, could help decide the fate of what's been the dominant hypothesis of the disease's cause.

By Jonathan Gardner • Aug. 29, 2019

Amgen patents on Repatha invalid, judge rules in reversal

The decision by Judge Richard Andrews overturns a February jury verdict that affirmed two patents held by Amgen on the cholesterol drug.

By Ned Pagliarulo • Aug. 28, 2019

Immatics shows Celgene isn't done stocking cell therapy pipeline

As its takeover by Bristol-Myers nears closing, Celgene is committing $75 million to research into T-cell redirecting technology.

By Jonathan Gardner • Aug. 28, 2019